Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


1. Dormicum
2. Hydrochloride, Midazolam
3. Maleate, Midazolam
4. Midazolam
5. Midazolam Hydrochloride
6. Ro 21 3981
7. Ro 21-3981
8. Ro 213981
9. Versed
1. 59467-94-6
2. Midazolam Maleate Salt
3. Midazolam Maleate [usan]
4. Ro 21-3981/001
5. Midazolam (as Maleate)
6. Nsc-313452
7. Buccolam
8. Hypnovel
9. Versed
10. 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine Maleate (1:1)
11. 77520s18se
12. Ro-213981-003
13. Dormicum Maleate
14. Midazolam Maleate (usan)
15. Ro-21-3981/001
16. (z)-but-2-enedioic Acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine
17. 4h-imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-, (z)-2-butenedioate (1:1)
18. Einecs 261-775-0
19. Ro-21-3981/003
20. Unii-77520s18se
21. Schembl147776
22. Midazolam Maleate [mi]
23. Chembl2106922
24. Iti-111
25. Nvd-301
26. Midazolam Maleate [mart.]
27. Midazolam Maleate [who-dd]
28. Nsc313452
29. Nsc 313452
30. 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine Monomaleate
31. D05028
32. 467m946
33. Q27266551
34. 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Maleate
35. 4h-imidazo[1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-, (z)-2-butenedioate (1:1)
| Molecular Weight | 441.8 g/mol |
|---|---|
| Molecular Formula | C22H17ClFN3O4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 3 |
| Exact Mass | 441.0891619 g/mol |
| Monoisotopic Mass | 441.0891619 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 590 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).
Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.
For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
Anesthetics, Intravenous
Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174) (See all compounds classified as Anesthetics, Intravenous.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
N05CD08

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Hemay005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Lead Product(s): Hemay005,Midazolam Maleate
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2024

Lead Product(s) : Hemay005,Midazolam Maleate
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets
Details : Hemay005 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Lead Product(s): Ivarmacitinib,Midazolam Maleate,Warfarin Sodium,Omeprazole,Vitamin K1,Repaglinide
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivarmacitinib,Midazolam Maleate,Warfarin Sodium,Omeprazole,Vitamin K1,Repaglinide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR0302 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
HRS5091 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.
Lead Product(s): HRS5091,Midazolam Maleate,Warfarin Sodium,Omeprazole,Vitamin K1,Digoxin,Rosuvastatin Calcium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HRS5091,Midazolam Maleate,Warfarin Sodium,Omeprazole,Vitamin K1,Digoxin,Rosuvastatin Calcium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HRS5091 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hepatitis B, Chronic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be offered.
Lead Product(s): Midazolam Maleate,Inapplicable
Therapeutic Area: Neurology Brand Name: Buccolam
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Neuraxpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam Maleate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Neuraxpharm Expands Its Business in Southeast Europe
Details : Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be off...
Product Name : Buccolam
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
Lead Product(s): Midazolam Maleate,Inapplicable
Therapeutic Area: Neurology Brand Name: Buccolam
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam Maleate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Neuraxpharm Launches First Product in Japan
Details : Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.
Product Name : Buccolam
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.
Lead Product(s): Midazolam Maleate,Inapplicable
Therapeutic Area: Neurology Brand Name: Buccolam
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Permira
Deal Size: $1,880.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam Maleate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Permira
Deal Size : $1,880.0 million
Deal Type : Acquisition
Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm
Details : The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expa...
Product Name : Buccolam
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics and Ireland.
Lead Product(s): Midazolam Maleate,Inapplicable
Therapeutic Area: Neurology Brand Name: Buccolam
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Neuraxpharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 14, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam Maleate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Neuraxpharm Acquires Market-Leading Buccolam® For Emergency Treatment of Epileptic Children
Details : Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics an...
Product Name : Buccolam
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 14, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
50
PharmaCompass offers a list of Midazolam Maleate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Midazolam Maleate manufacturer or Midazolam Maleate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Midazolam Maleate manufacturer or Midazolam Maleate supplier.
PharmaCompass also assists you with knowing the Midazolam Maleate API Price utilized in the formulation of products. Midazolam Maleate API Price is not always fixed or binding as the Midazolam Maleate Price is obtained through a variety of data sources. The Midazolam Maleate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Midazolam Maleate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Midazolam Maleate, including repackagers and relabelers. The FDA regulates Midazolam Maleate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Midazolam Maleate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Midazolam Maleate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Midazolam Maleate supplier is an individual or a company that provides Midazolam Maleate active pharmaceutical ingredient (API) or Midazolam Maleate finished formulations upon request. The Midazolam Maleate suppliers may include Midazolam Maleate API manufacturers, exporters, distributors and traders.
click here to find a list of Midazolam Maleate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Midazolam Maleate DMF (Drug Master File) is a document detailing the whole manufacturing process of Midazolam Maleate active pharmaceutical ingredient (API) in detail. Different forms of Midazolam Maleate DMFs exist exist since differing nations have different regulations, such as Midazolam Maleate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Midazolam Maleate DMF submitted to regulatory agencies in the US is known as a USDMF. Midazolam Maleate USDMF includes data on Midazolam Maleate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Midazolam Maleate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Midazolam Maleate suppliers with USDMF on PharmaCompass.
A Midazolam Maleate written confirmation (Midazolam Maleate WC) is an official document issued by a regulatory agency to a Midazolam Maleate manufacturer, verifying that the manufacturing facility of a Midazolam Maleate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Midazolam Maleate APIs or Midazolam Maleate finished pharmaceutical products to another nation, regulatory agencies frequently require a Midazolam Maleate WC (written confirmation) as part of the regulatory process.
click here to find a list of Midazolam Maleate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Midazolam Maleate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Midazolam Maleate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Midazolam Maleate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Midazolam Maleate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Midazolam Maleate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Midazolam Maleate suppliers with NDC on PharmaCompass.
Midazolam Maleate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Midazolam Maleate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Midazolam Maleate GMP manufacturer or Midazolam Maleate GMP API supplier for your needs.
A Midazolam Maleate CoA (Certificate of Analysis) is a formal document that attests to Midazolam Maleate's compliance with Midazolam Maleate specifications and serves as a tool for batch-level quality control.
Midazolam Maleate CoA mostly includes findings from lab analyses of a specific batch. For each Midazolam Maleate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Midazolam Maleate may be tested according to a variety of international standards, such as European Pharmacopoeia (Midazolam Maleate EP), Midazolam Maleate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Midazolam Maleate USP).